Skip to content

How dextrose prolotherapy can help relieve persistent temporomandibular joint pain and improve jaw function

Dextrose prolotherapy effect in improving the temporomandibular joint disc displacement symptoms without reduction refractory to conservative treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN63941479
Enrollment
20
Registered
2025-01-21
Start date
2023-08-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporomandibular joint disc displacement without reduction Musculoskeletal Diseases

Interventions

Patients with symptoms of unilateral DDwoR with limited mouth opening were randomly assigned into two equal groups using the randomization tool from https://www.randomizer.org/. The study group receiv

Sponsors

Damascus University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18 and 35 years old with symptoms of unilateral DDwoR with limited mouth opening (=1 month) mentioned in the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD), maximum assisted opening <40 mm, and restricted mouth opening that interferes with the ability to eat 2. Conservative treatments (pharmacological-physical) failed to improve their symptoms 3. Level pain=5 on the Numeric Rating Scale (NRS).

Exclusion criteria

Exclusion criteria: 1. Allergy to dextrose 2. Having parafunctional habits 3. Restriction of mouth opening by spasm muscles or joint adherence 4. Previous exposure to IAI 5. Unwillingness to continue

Design outcomes

Primary

MeasureTime frame
Pain assessed using the Visual Analogue Scale (VAS) at four timepoints: before injection (T0), 2 weeks after treatment (T1), 2 months after treatment (T2), and 6 months after treatment (T3)

Secondary

MeasureTime frame
Unassisted maximum interincisal opening (MIO), including overlap, was measured using a millimeter-scaled ruler at the same time points: before injection (T0), 2 weeks after treatment (T1), 2 months after treatment (T2), and 6 months after treatment (T3)

Countries

Syria

Contacts

Public ContactYazan Sayed Taleb
yazan44.sayed@damascusuniversity.edu.sy+963 (0)991195863

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 14, 2026